Expert committee on introduction of incretin-based therapy in Russia: advance and failure
https://doi.org/10.14341/2072-0351-6095
Abstract
Short resume of expert committees meeting about problems of using of incretin-based therapy in Russian Federation.
References
1. Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab. 2011 Jan;13(1):55-64. doi: 10.1111/j.1463-1326.2010.01325.x.
2. Sinclair AJ, Paolisso G, Castro M, Bourdel-Marchasson I, Gadsby R, Rodriguez Mañas L; European Diabetes Working Party for Older People. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes Metab. 2011 Nov;37 Suppl 3:S27-38.
3. Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S. 52-week efficacy and safety of vildagliptin versus glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009 Feb;11(2):157-166.
4. Ligueros-Saylan М, Schweizer А, Dickinson S, Kothny W. Vildagliptin therapy is not associated with an increased risk of pancreatitis. Diabetologia. 2009;52(Supp l): S303.
5. Kothny W, Schweizer A, Dickinson S, Ligueros-Saylan M. Hepatic safety profile of vildagliptin, a new DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetologia. 2009;52(Supp l): S301.
6. Foley J, Hoffmann Р, Liguecos-Saylan М, Schweizer A, Kothny W. Lack of vildagliptin effects on the immune system. Diabetologia. 2009;52(Supp l): S304-S305.
7. Sesso HD, Stampfer MJ, Rosner B, Hennekens CH, Gaziano JM, Manson JE, Glynn RJ. Systolic and diastolic blood pressure, pulse pressure and mean arterial pressure as predictors of cardiovascular disease risk in men. Hypertension. 2000 Nov;36(5):801-807.
8. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, Diabetes, and Cardiovascular Events. Diabetes Care. 2010 Jun;33(6):1389-1394.
9. Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, Couturier A, Foley JE, Zinman B. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010 Sep;12(9):780-789.
10. Devendra D, Gohel B, Bravis V, Hui E, Salih S, Mehar S, Hassanein M. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract. 2009 Oct;63(10):1446-1450. Epub 2009 Aug 12.
11. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007 Jun;50(6):1148-1155. Epub 2007 Mar 27.
12. Алгоритмы специализированной медицинской помощи больным сахарным диабетом, 5-й выпуск. Сахарный диабет. 2011; 116 с.
13. Дедов ИИ, Шестакова МВ, Аметов АС, Анциферов МБ, Галстян ГР, Майоров АЮ, Мкртумян АМ, Петунина НА, Сухарева ОЮ. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии СД 2 типа. Сахарный диабет. 2011;(4):6-17.
14. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 Jun;35(6):1364-1379. Epub 2012 Apr 19.
15. International Diabetes Federation. Treatment Algorithm for People with Type 2 Diabetes. Available from: http://www.idf. org/treatment-algorithm-people-type-2-diabetes.
Review
For citations:
Expert committee on introduction of incretin-based therapy in Russia: advance and failure. Diabetes mellitus. 2012;15(3):117-120. (In Russ.) https://doi.org/10.14341/2072-0351-6095
Views:
404
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
